Predictors of impaired daytime sleep and wakefulness in patients with Parkinson disease treated with older (ergot) vs newer (nonergot) dopamine agonists.
about
Religiosity in patients with Parkinson's disease.Neurobehavioral mechanisms of temporal processing deficits in Parkinson's disease.Daytime sleepiness and Parkinson's disease: the contribution of the multiple sleep latency test.Daytime sleepiness in Parkinson's disease: a reappraisal.Parkinson's disease sleep scale, sleep logs, and actigraphy in the evaluation of sleep in parkinsonian patients.Nonmotor symptoms groups in Parkinson's disease patients: results of a pilot, exploratory studyExcessive daytime sleepiness and unintended sleep episodes associated with Parkinson's disease.Modafinil for daytime somnolence in Parkinson's disease: double blind, placebo controlled parallel trial.Correlating subjective and objective sleepiness: revisiting the association using survival analysis.Sleepiness in Idiopathic REM Sleep Behavior Disorder and Parkinson Disease.Caffeine for treatment of Parkinson disease: a randomized controlled trial.Daytime REM sleep in Parkinson's disease.A comprehensive approach to Parkinson's disease. How to manage fluctuating motor and nonmotor symptoms.Volumetric correlates of cognitive functioning in nondemented patients with Parkinson's diseaseDaytime alertness in Parkinson's disease: potentially dose-dependent, divergent effects by drug class.Update on the use of pramipexole in the treatment of Parkinson's disease.The Treatment of Sleep Disorders in Parkinson's Disease: From Research to Clinical Practice.Excessive daytime sleepiness in patients with Parkinson's disease.When Parkinson's disease patients go to sleep: specific sleep disturbances related to Parkinson's disease.Sleep-disordered breathing in neurodegenerative diseases.Effects of rotigotine on Parkinson's disease-related sleep disturbances.Effects of rotigotine transdermal system on non-motor symptoms in Parkinson's disease: an overview.Treatment of the sleep disorders associated with Parkinson's diseaseSleep/wake problems in Parkinson's disease: pathophysiology and clinicopathologic correlations.Safety overview of FDA-approved medications for the treatment of the motor symptoms of Parkinson's disease.A review of adverse events linked to dopamine agonists in the treatment of Parkinson's disease.Excessive Daytime Sleepiness Predicts Neurodegeneration in Idiopathic REM Sleep Behavior Disorder.White-matter changes correlate with cognitive functioning in Parkinson's disease.Visual symptoms in Parkinson's disease and Parkinson's disease dementia.The nature of excessive sleepiness and sudden sleep onset in Parkinson׳s disease.Sleepiness and Depression in Parkinson's Disease Patients Treated with Ropinirole and Levodopa.Sleep dysfunction and its management in Parkinson's disease.Daytime sleepiness in Parkinson's disease: perception, influence of drugs, and mood disorder.Fatigue and excessive daytime sleepiness in idiopathic Parkinson's disease differently correlate with motor symptoms, depression and dopaminergic treatment.Activity-rest rhythm abnormalities in Parkinson's disease patients are related to dopaminergic therapy.Body side and predominant motor features at the onset of Parkinson's disease are linked to motor and nonmotor progression.Longitudinal study of levodopa in Parkinson's disease: effects of the advanced disease phase.Progressive dopamine and hypocretin deficiencies in Parkinson's disease: is there an impact on sleep and wakefulness?Effect of chronic kidney disease on excessive daytime sleepiness in Parkinson disease.Life goals of patients with Parkinson's disease: A pilot study on correlations with mood and cognitive functions.
P2860
Q30376722-E2A802C3-DA5B-4294-9FAD-40AB9CEEFEA1Q33833680-D2F8851B-B1FC-4B8F-9E39-21FB6ADB9142Q33999968-9CB2CC1A-3B64-4BFB-A805-4E50D4FD61A6Q34150079-98C1E02F-3F85-40FF-9475-A4ECAD8D67C3Q34901847-5BE15480-CED8-4BDC-9ABD-552CFA25E735Q35028869-0C43D170-12E0-4CB6-ABD1-634B6ADFBFEFQ35211225-103DDABC-8862-4DD5-B461-2ADBCF54010AQ35485478-5D1D4429-5E8F-4BA8-B2F7-CE23FD3D5802Q35529531-1DBE3F75-69DE-4361-A0A6-3771B7B17029Q36076655-BF28F46E-E327-43E0-A620-7BC624234BB8Q36149963-B7C34067-2723-4AD3-8EA3-858E9B8E1ACAQ36451550-ABE750DD-FD8C-46B9-8714-87E2DA123823Q36567733-B858BC43-55E2-4FAF-830B-08B0330275FEQ36592670-EC404E13-049E-4F90-9D6B-D9AB55D248CFQ36659079-82409BFE-CFC7-4A0C-92A9-B38BB1899C45Q36842189-E3DABC71-BD19-4D4C-9606-122C018FDF5FQ37643888-1FBB896F-62C8-43EF-99C3-7E61DBAFBFC9Q37842431-AD2B174F-971C-4E37-9451-F8127E74CC49Q37874195-91E0D9D5-F9A6-4735-9AAA-7C01B632919AQ37976297-73846781-7036-41C0-9778-79B8E16CDBBAQ38153751-DA927370-C29C-4A94-87C9-4C256FF5AD23Q38162942-8DBB19C8-7C5C-4BB2-AEE7-43AD8024EFCEQ38165855-41EBFA8F-D8C6-49A4-B859-334CE78F2449Q38214475-144EFA70-6EE6-4181-8591-BC0112A3729FQ38223072-E65E5A6C-5D47-45ED-8E9E-4C5896BB5EAEQ38662579-1B499E44-A3EA-44AE-A19A-CEC6FBC966E5Q38886330-BA7429CC-897C-4487-8595-324AA72D8DA1Q39427708-FBC9FE16-7E40-4BE2-B3F0-85D416AC6A24Q39703424-7F8BA0F4-1B6F-4E6D-9190-9895FE0DD1B8Q40412762-A0BB4970-7539-4F91-A388-44F55DFEE955Q41675120-83A2AAF4-7A25-4AB3-A114-4525F35FB0E3Q41819301-D4DC53D5-2B3A-41C0-BD7E-122AFC882866Q41946113-47EF1DB7-9D59-42D8-B8BF-E8038426E3E5Q43057272-F4720696-1F25-4957-93E6-70758121E67EQ43175529-91FC8E84-18C9-488D-99A4-DED841ABC731Q47712767-795D284F-6209-4D3C-925A-917392543190Q48172859-9556A690-1DC6-4CF1-B813-421963022B70Q48235911-25E52EF6-BBF4-49FE-8162-A5AA071522BFQ48310921-6B8BDF00-6B17-4CB7-B706-C9645C8D1CE8Q48430038-C12718A5-A219-4ECF-B8CA-1AABAA3D6186
P2860
Predictors of impaired daytime sleep and wakefulness in patients with Parkinson disease treated with older (ergot) vs newer (nonergot) dopamine agonists.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
Predictors of impaired daytime ...... (nonergot) dopamine agonists.
@en
Predictors of impaired daytime ...... son disease treated with older
@nl
type
label
Predictors of impaired daytime ...... (nonergot) dopamine agonists.
@en
Predictors of impaired daytime ...... son disease treated with older
@nl
prefLabel
Predictors of impaired daytime ...... (nonergot) dopamine agonists.
@en
Predictors of impaired daytime ...... son disease treated with older
@nl
P921
P356
P1433
P1476
Predictors of impaired daytime ...... (nonergot) dopamine agonists.
@en
P2093
Ajmal Razmy
Colin M Shapiro
P304
P356
10.1001/ARCHNEUR.61.1.97
P50
P577
2004-01-01T00:00:00Z